S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Dr. Jared Giatras on Botox for TMJ Relief and Facial Contouring

Beyond its reputation for smoothing wrinkles, Botox is emerging as a dual-purpose tool for patients suffering from chronic jaw tension. Dr. Jared Giatras of Giatras Family Dentistry in Murfreesboro, Tennessee, recently detailed how the treatment addresses both the functional pain of TMJ and the aesthetic desire for facial slimming.

The procedure targets the masseter muscle, the primary muscle responsible for chewing. When patients suffer from chronic clenching or grinding, this muscle often becomes hyperactive and enlarged, leading to significant jaw soreness and a wider lower facial profile. By injecting Botox into these specific areas, practitioners effectively relax the muscle, which alleviates tension and gradually reduces its volume over several weeks.

Dr. Giatras notes that this process offers a nonsurgical route to a softer jawline while simultaneously providing relief from discomfort. However, the treatment is not a universal solution for all jaw pain. Success relies heavily on a precise understanding of individual facial anatomy and the root cause of the symptoms. Before proceeding, providers must evaluate whether an enlarged masseter is the primary driver behind a patient’s discomfort or their perceived facial width. By aligning treatment plans with specific anatomical needs, patients can achieve functional relief and subtle, natural-looking contouring without the risks associated with surgery.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!